Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 5—May 2010

Letter

Increase in Pneumococcus Macrolide Resistance, USA

Suggested citation for this article

To the Editor: Jenkins and Farrell reported an increase in the proportion of macrolide-resistant Streptococcus pneumoniae isolates in the United States (1). They mentioned increased use and inappropriate prescription of macrolides as potential explanations for the increase in macrolide resistance and expressed doubts, stating “which (if any) of these factors might explain the trends here are not clear.” Although the spread of antimicrobial drug resistance is a complex issue with many contributing factors, we believe that the role of macrolide use should not be understated.

Several studies in Europe have provided evidence for a relationship between macrolide use and resistance. Macrolide exposure leads to emergence of macrolide resistance on the individual level, and countries in Europe with higher outpatient sales of macrolides have more macrolide-resistant pneumococci (2).

Outpatient antimicrobial drug use in the United States has decreased since 1995–1996, especially among children. However, use of azithromycin increased in children, and use of macrolides increased in older patients from 1995–1996 through 2005–2006 (3). In this context, it would be surprising that after this increase, pneumococci would show different characteristics in the United States than in Europe. A 2001 study showed that increased macrolide use in the United States during 1995–1999 coincided with a doubling of the proportion of macrolide-resistant pneumococci (4), and further increases in macrolide use since 1999 (3) have contributed to the increase in macrolide-resistant pneumococci.

Decreased macrolide use has led to a decrease in macrolide-resistant pneumococci. A yearly seasonal reduction in antimicrobial drug prescribing in Israel was associated with a decrease in the proportion of antimicrobial drug–resistant pneumococci that caused acute otitis media (5). With the introduction of expanded-valent pneumococcal conjugate vaccines, there is promise that drug-resistant pneumococcal disease can be reduced. Nevertheless, judicious use of antimicrobial drugs and a decrease in unnecessary prescriptions, as promoted by the Get Smart: Know When Antibiotics Work (www.cdc.gov/getsmart) campaign, are essential to limiting selection and spread of antimicrobial drug resistance.

Lauri A. HicksComments to Author , Dominique L. Monnet, and Rebecca M. Roberts
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.A. Hicks, R.M. Roberts); European Centre for Disease Prevention and Control, Stockholm, Sweden (D.L. Monnet)

References

  1. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009;15:12604. DOIPubMed
  2. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:57987.PubMed
  3. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302:75866. DOIPubMed
  4. Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286:185762. DOIPubMed
  5. Dagan R, Barkai G, Givon-Lavi N, Sharf A, Vardy D, Cohen T, Seasonality of antibiotic-resistant Streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy? J Infect Dis. 2008;197:1094102. DOIPubMed

Suggested citation for this article: Hicks LA, Monnet DL, Roberts RM. Increase in pneumococcus macrolide resistance, USA [letter]. Emerg Infect Dis [serial on the Internet]. 2010 May [date cited]. http://wwwnc.cdc.gov/eid/article/16/5/09-1424

DOI: 10.3201/eid1605.091424

Related Links

Table of Contents – Volume 16, Number 5—May 2010

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Lauri A. Hicks, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop C23, Atlanta, GA 30333, USA


character(s) remaining.

Comment submitted successfully, thank you for your feedback.

TOP